• 1
    Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007; 448: 427434.
  • 2
    Agace WW. Tissue-tropic effector T cells: generation and targeting opportunities. Nat Rev Immunol. 2006; 6: 682692.
  • 3
    von Adrian UH, Engelhardt B. Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med. 2003; 348: 6872.
  • 4
    Tysabri (natalizumab) package insert 2010.
  • 5
    Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005; 353: 19121925.
  • 6
    Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial. Gastroenterology. 2007; 132: 16721683.
  • 7
    Wehner NG, Gasper C, Shopp G, et al. Immunotoxicity profile of natalizumab. J Immunotoxicol. 2009; 6: 115129.
  • 8
    Fuh F, David C, Hwang O, et al. Gut-homing CD4+ lymphocytes are specifically targeted in cynomolgus monkeys dosed with anti-beta7 antibodies. Gastroenterology. 2008; 134( 4, Suppl 1): A99. Abstract 703.
  • 9
    Soler D, Chapman T, Yang LL, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009; 330: 864875.
  • 10
    Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med. 2010; 61: 3547.
  • 11
    Hesterberg PE, Winsor-Hines D, Briskin MJ, et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology. 1996; 111: 13731380.
  • 12
    Schippers A, Leuker C, Pabst O, et al. Mucosal addressin cell-adhesion molecule-1 controls plasma-cell migration and function in the small intestine of mice. Gastroenterology. 2009; 137: 924933.
  • 13
    Gelzleichter TR, Hiraragi, H, Stefanich EG, et al.Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta 7 integrin antagonists. Patent application. US 2010/0255508 A1 07 Oct 2010.
  • 14
    Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med. 2003; 348: 2432.
  • 15
    Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med. 2005; 352: 24992507.
  • 16
    Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol. 2008; 6: 13701377.
  • 17
    Bonig H, Wundes A, Chang KH, et al. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood. 2008; 111: 34393441.
  • 18
    Zohren F, Toutzaris D, Klärner V, et al. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood. 2008; 111: 38933895.
  • 19
    Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003; 348: 1523.
  • 20
    Banerjee ER, Latchman YE, Jiang Y, et al. Distinct changes in adult lymphopoiesis in Rag2−/− mice fully reconstituted by alpha4-deficient adult bone marrow cells. Exp Hematol. 2008; 36: 10041013.
  • 21
    Brakebusch C, Fillatreau S, Potocnik AJ, et al. Beta1 integrin is not essential for hematopoiesis but is necessary for the T cell-dependent IgM antibody response. Immunity. 2002; 16: 465477.